303 related articles for article (PubMed ID: 11951079)
1. Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.
Ciepłuch H; Baran W; Hellmann A
Med Sci Monit; 2002 Apr; 8(4):PI31-6. PubMed ID: 11951079
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
3. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P
Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide treatment of resistant or relapsed multiple myeloma patients.
Hus M; Dmoszynska A; Soroka-Wojtaszko M; Jawniak D; Legiec W; Ciepnuch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Manko J;
Haematologica; 2001 Apr; 86(4):404-8. PubMed ID: 11325647
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Hoiczyk M; Flasshove M; Hense J; Bojko P; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2005 Jan; 74(1):40-6. PubMed ID: 15613105
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
[TBL] [Abstract][Full Text] [Related]
7. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of thalidomide in refractory multiple myeloma.
Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B
N Engl J Med; 1999 Nov; 341(21):1565-71. PubMed ID: 10564685
[TBL] [Abstract][Full Text] [Related]
9. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Berenson JR; Lichtenstein A; Porter L; Dimopoulos MA; Bordoni R; George S; Lipton A; Keller A; Ballester O; Kovacs MJ; Blacklock HA; Bell R; Simeone J; Reitsma DJ; Heffernan M; Seaman J; Knight RD
N Engl J Med; 1996 Feb; 334(8):488-93. PubMed ID: 8559201
[TBL] [Abstract][Full Text] [Related]
11. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
[TBL] [Abstract][Full Text] [Related]
12. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
13. [Single-agent thalidomide for advanced and refractory multiple myeloma].
Okikawa Y; Takimoto Y; Noda M; Imagawa J; Katayama Y; Sakai A; Okita H; Fujimura K; Kimura A
Rinsho Ketsueki; 2003 Jun; 44(6):368-74. PubMed ID: 12884814
[TBL] [Abstract][Full Text] [Related]
14. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Tosi P; Zamagni E; Cellini C; Plasmati R; Cangini D; Tacchetti P; Perrone G; Pastorelli F; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2005 Mar; 74(3):212-6. PubMed ID: 15693790
[TBL] [Abstract][Full Text] [Related]
15. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
Prince HM; Mileshkin L; Roberts A; Ganju V; Underhill C; Catalano J; Bell R; Seymour JF; Westerman D; Simmons PJ; Lillie K; Milner AD; Iulio JD; Zeldis JB; Ramsay R
Clin Cancer Res; 2005 Aug; 11(15):5504-14. PubMed ID: 16061867
[TBL] [Abstract][Full Text] [Related]
16. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.
Offidani M; Corvatta L; Marconi M; Malerba L; Mele A; Olivieri A; Brunori M; Catarini M; Candela M; Capelli D; Montanari M; Rupoli S; Leoni P
Eur J Haematol; 2004 Jun; 72(6):403-9. PubMed ID: 15128418
[TBL] [Abstract][Full Text] [Related]
17. Unstable plasma thalidomide concentration in patients with refractory multiple myeloma.
Kodama T; Horiuchi R; Tsukamoto N; Nojima Y; Murakami H
Lab Hematol; 2004; 10(3):132-6. PubMed ID: 15479647
[TBL] [Abstract][Full Text] [Related]
18. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
Ai Zheng; 2007 Dec; 26(12):1369-72. PubMed ID: 18076804
[TBL] [Abstract][Full Text] [Related]
20. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
Morris TC; Kettle PJ; Drake M; Jones FC; Hull DR; Boyd K; Morrison A; Clarke P; O'Reilly P; Quinn J
Br J Haematol; 2008 Nov; 143(3):349-54. PubMed ID: 18759764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
